Single-Cell RNA-Seq Datasets of residual AML cells purifed from Patient Derived Xenograft bone marrow treated or not with venetoclax plus cytarabine [Patient TUH07]

The goal of this study is to compare single cell transcriptome of in vivo AML cells profiling before treatment and after venetoclax and cytarabine in single agent or after the duplet. This study uncovered transcriptionally different cell subpopulations that specifically emerge in VEN+AraC residual disease. Residual AML cells purifed from bone marrow of patient samples xenografted in 8 weeks NOD/LtSz-SCID/IL-2Rγchain null (NSG) mice and treated for 5 days with AraC treatment by intra-peritoneal injection alone or in association with 7 days of venetoclax treatment by oral gavage. Viable primary human AML cells from mice bone marrow of PDX before treatment or following AraC, venetoclax treatment or venetoclax plus AraC doublet therapy were isolated using cell sorter cytometer. To generate single-cell libraries the Chromium Single Cell 3' Reagent Kits (v3 Chemistry, 10x Genomics) was used and the sequencing-ready library was cleaned up prior to sequencing on a NextSeq550 instrument (Illumina). The single-cell RNA data was processed using cellranger v.3.0.2. and analyzed with the R package Seurat v.3.0.